Melanoma immunotherapy has a critical limitation: 40 to 60% of patients don’t respond. Arielle Elkrief, MD, discusses an innovative approach targeting the gut microbiome. By using fecal microbiota…
Muneeb Shah MD, and Luke Maxfield, MD, break down the essentials of skin cancer, explaining the causes, symptoms, and treatments of basal cell carcinoma, squamous cell carcinoma, and…
Advances in surgical treatments of melanoma have changed how surgeons treat patients with melanoma. According to Richard L. Shapiro, MD, associate professor in the Department of Surgery at…
Results from a cohort study suggest that vision loss, a common side effect after plaque radiotherapy for uveal melanoma, may be mitigated or avoided entirely thanks to prophylactic…
The constantly evolving science and emerging study results focused on adjuvant therapies have drastically changed the treatment landscape for patients with melanoma. Along with targeted therapies, immunotherapies have…
The research team led by Alexander Eggermont, MD, PhD, of the Gustave Roussy Cancer Campus Grand Paris, found that among over 1,000 stage III patients with melanoma treated…
Working with the theory that it would be possible to detect immune reinvigoration related to disease-free survival in various stages of melanoma, lead investigator Alexander C. Huang, MD,…
After prior case studies showed promising results with PD-1 inhibition followed by chemotherapy, a group of doctors, led by Georgia Sofia Karachaliou, MD, MSc, of the Department of Medicine…
Published final results of the DeCOG-SLT trial add evidence that patients who have a positive sentinel lymph-node biopsy, and have immediate complete lymph node dissection, do not achieve…
There have been many changes in the treatment landscape of stage II and stage III melanoma over the past decade. This article takes a look at the benefits…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review by Anna C. Pavlick, DO, MBA, of New York University…
Determining which patients are most likely to benefit from BRAF-targeted therapies was the topic of a recent review in ASCO Educational Book by Anna C. Pavlick, DO, MBA,…
